{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000067","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.385743+00:00","generated_at":"2026-06-10T03:43:54.388339+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine settles INGREZZA patent litigation; generic entry delayed to 2040","bullets":["Settlement with Sandoz and Crystal grants generic INGREZZA license starting Feb 1, 2040, or earlier under certain conditions.","Patent litigation resolved for one ANDA filer; two other ANDA challenges remain pending with trial set for Jan 2, 2024.","Agreement to be submitted to FTC and DOJ as required by law.","INGREZZA is Neurocrine's drug for tardive dyskinesia and Huntington's chorea."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000067","json":"https://secwatch.observer/filing/0000914475-23-000067.json","markdown":"https://secwatch.observer/filing/0000914475-23-000067.md","text":"https://secwatch.observer/filing/0000914475-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000067/0000914475-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000067/nbix-20231005.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:43:54.388339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}